• About
  • Pipeline
  • Investor
  • News
  • Contact
  • About
  • Pipeline
  • Investor
  • News
  • Contact
  • Releases

    Q&A session – topline data from Study 0205

    Published: 4. January, 2024

    Link to release: (Link to Q&A session-image)

    Link to release: (Link to Q&A session-image)

    https://cessatech.com/wp-content/uploads/2024/01/QA-study-0205_video_LS.mp4

    Related articles

    Releases

    24. July, 2026

    Proveca intends to request a re-examination of CHMP opinion for CT001/KemSu

    The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted...

    Read more

    Releases

    12. June, 2026

    Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet

    Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children  ...

    Read more

    Releases

    28. May, 2026

    Financial Report Q1-2026

    Cessatech today announced the interim report for the three months ended March 31, 2026....

    Read more

    Stay up to date!

    Subscribe and get notified on Cessatech's latest news.
    An acceptance email will be sent to you, please check your spam.

    Almost there! Please check your inbox to confirm your subscription to Cessatech.

    Cessatech info
    • Cessatech A/S
      CVR: DK41293055
    • Strandvejen 60
    • DK-2900 Hellerup
    • +45 5352 2309
    • info@cessatech.com
    More information
    • About
    • Pipeline
    • Contact
    News
    • Releases
    • Facts
    • All